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background activity (Fig. 1b) paralleling the progressive development of cortical atrophy on brain MRIs.
Negative genetic investigations include direct sequencing of: GLRA1, CRFL1, SCN4A, PRRT2, SCN2A, CLCN1, ARHGEF9, SLC2A1, ATP1A3, CACNA1A, POLG1, UBE3A, and KCNQ2. Array-CGH is noncontributory. He underwent an extended neurometabolic work-up: ammonia, serum and CSF lactate, urinary organic acids and mucopolysaccharides, plasma aminoacids, acylcarnitines, sialo-transferrins and very long chain fatty acids, CSF neurotransmitters, serum auto-antibodies (anti-NMDAR, LG1, CASPR and GABA2), skin and muscle biopsy (histology and mitochondrial respiratory chain activity): all normal. Clinical, genetic and brain MRI data are summarized in Table 1 .
Molecular testing for the SCN1A gene documented the heterozygous, de novo missense c.628 T > C (p.Ser228Pro) variant, classified as likely pathogenic. Whole exome sequencing with deletions/duplications (Copy Number Variants, CNV) analysis, independently performed by a different laboratory and targeting all protein coding exons, exon-intron boundaries ( ± 20bps) and selected non-coding clinicallyrelevant variants, confirmed this finding with no additional variants in previously established disease genes. Results are validated by bidirectional direct Sanger sequencing. The variant is absent from Genome Aggregation Database, predicted to be deleterious by the in silico prediction tools SIFT and MutationTaster (while PolyPhen predicts it as tolerated) and reported in ClinVar as likely pathogenic (ID375512).
Our case shares various clinical features with early infantile SCN1A epileptic encephalopathy: early-onset, severe developmental encephalopathy resulting in profound developmental delay (non-verbal as https://doi.org/10.1016/j.seizure.2019.01.002 Received 31 October 2018; Received in revised form 6 December 2018; Accepted 2 January 2019 T in 8/9 cases in [2] and not sitting unsupported, due to hypotoniaunusual in DS, but encountered in 9/9 cases in [2] ), pharmacoresistant epilepsy with multiple seizure types, a prominent hyperkinetic movement disorder, and non-specific neuroimaging findings (normal neonatal MRI followed by cortical atrophy, present in 2/9 in [2] ).
However, there are also some differences to highlight: first, onset occurred in the first hours of life compared to the early-infantile period, and was characterized by tonic spasms mainly induced by tactile stimulation, in the absence of clear-cut EEG changes, which led to suspect hyperekplexia.
Second, the presence of diffuse stiffness, clubfeet, hip dysplasia and multiple contractures is unreported (only scoliosis/kyphoscoliosis were reported in 2/9 cases)2.
Third, our mutation is different from the ones so far associated with early infantile SCN1A encephalopathy. Sadleir and colleagues described a total of 9 cases, 8 carrying the c.677C > T (p.Thr226Met) variant [2] , and the remaining one the c.4033C > T (p.Pro1345Ser) [2] variant. One more case (retrospectively thought to have a phenotype consistent with early-infantile SCN1A encephalopathy) carryied the c.1264 G > T (p.Val422Leu) variant [3] .
However, our view is that the mutation we found, classified as likely pathogenic and occurring de novo, should be regarded as causative of our patient's phenotype, although with previously unreported, peculiar features when compared to early infantile SCN1A encephalopathy. Having performed whole exome sequencing with deletions/duplication analysis and CGH-array in addition to a targeted NGS, a contribution of additional genetic variants or CNV is to be considered unlikely, although it is not possible to completely exclude a pathogenic contribution by uncoding regions not covered by our test or by other yet undetectable epigenetic factors. 
